Inovio Pharmaceuticals Stock News

Options bulls are blasting Inovio Pharmaceuticals Inc  (NASDAQ:INO) after Jefferies hiked its price target to $8 from $4.50 on Friday.

The consensus price target hints at a 122.9% upside potential for Inovio (INO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President and Ch

The mean of analysts' price targets for Inovio (INO) points to a 146.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

Inovio (INO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in th

PLYMOUTH MEETING, Pa. , Feb. 7, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela

The average of price targets set by Wall Street analysts indicates a potential upside of 223.7% in Inovio (INO). While the effectiveness of this highly sought-after metric is questionable, the positiv

Inovio Pharmaceuticals (NASDAQ: INO ) stock is taking a beating on Wednesday as the biotechnology company prepares for a reverse stock split. The company's shares will undergo a one-for-12 reverse st

Inovio Pharma (INO) surges 134% in a month, mainly due to its plans to submit a regulatory application seeking approval of its lead candidate, INO-3107, in the second half of 2024 to treat RRP.

These companies in the biotechnology sector are doing incredible work and achieving wonderful developments. The result is not not only growth and profit for the companies, but they are also offering e

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacque Shea - President and Chi

Biotechnology company Inovio saw its shares jump after the US FDA communicated that data from Inovio completed Phase 1/2 trial of INO-3107 for treating Recurrent Respiratory Papillomatosis (RRP) could

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 25th Annual Global Investment Conference Call September 12, 2023 4:30 PM ET Company Participants Jacqueline Shea - President and Chief Execut

We gave Inovalis REIT our first review in December 2022. We noted that the NAV estimates were optimistic and crystallization of that value was improbable in the short term. We review where the REIT st

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Jefferies Healthcare Conference 2023 June 9, 2023 8:00 PM ET Company Participants Jacqueline Shea - President & CEO Michael Sumner - CMO Conference Call Part